Efficacy of cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn’s disease—A prospective nationwide multicenter cohort study
Wiener klinische Wochenschrift · 2024
DOI: 10.1007/s00508-023-02283-4 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Wiener klinische Wochenschrift, 2024. Verfasst von Christopher Dawoud und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Division of Visceral Surgery, Medical University Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. Hauptthemen laut MEDLINE: Crohn Disease, Rectal Fistula. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.
Abstract (Originalsprache)
Background
The use of mesenchymal stem cells is considered a novel and promising therapeutic option for patients with perianal fistulizing Crohn’s disease; however, data on its clinical application remain scarce. This multicenter nationwide study aimed to assess the clinical efficacy of mesenchymal stem cells in closing complex anal fistulas.
Methods
In this study 14 Crohn’s disease patients (3 males, 11 females) with complex anal fistulas treated in 3 tertiary hospitals in Austria were included between October 2018 and April 2021. Injection of 120 million allogeneic expanded adipose-derived mesenchymal stem cells (Cx601—darvadstrocel) was performed in each patient. Closure of the external fistula opening without secretion by external manual compression was defined as treatment success.
Results
The median age of the patient population at the time of surgery was 32 years (range 26–53 years) with a median body mass index of 21.7 kg/m 2 (range 16.7–26.6 kg/m 2 ). Of the patients 12 (86%) received monoclonal antibodies (infliximab, adalimumab, ustekinumab, vedolizumab) at the time of surgery. The median number of complex fistulas was 1.4 (range 1–2), The median operative time was 20 min (range 6–50 min) with no perioperative complications. After a median follow-up of 92 weeks, we found successful fistula closure in 57.1% ( n = 8) of treated patients. The perianal disease activity index did not improve significantly from initially 7 to a median of 6 after 52 weeks ( p = 0.495).
Conclusion
Darvadstrocel is a safe, minimally invasive surgical technique without significant perioperative complications. Clinical success can be expected in about half of the treated patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Surgery, Division of Visceral Surgery, Medical University Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
- Department of Visceral, Transplant and Thoracic Surgery, Centre for Operative Medicine, Medical University of Innsbruck, Innsbruck, Austria.
- First Surgical Department, Klinik Landstraße, Vienna, Austria.
- Department of Biomedical Imaging and Image-Guided Therapy, Medical University Vienna, Vienna, Austria.
- Department of General Surgery, Division of Visceral Surgery, Medical University Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. stefan.riss@meduniwien.ac.at.
Förderung
- Medical University of Vienna
Zitieren
APA
Dawoud, C., Widmann, K. M., Czipin, S., Pramhas, M., Scharitzer, M., Stift, A., Harpain, F., & Riss, S. (2024). Efficacy of cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn’s disease—A prospective nationwide multicenter cohort study. Wiener klinische Wochenschrift. https://doi.org/10.1007/s00508-023-02283-4
Vancouver
Dawoud C, Widmann KM, Czipin S, Pramhas M, Scharitzer M, Stift A, et al. Efficacy of cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn’s disease—A prospective nationwide multicenter cohort study. Wiener klinische Wochenschrift. 2024. doi:10.1007/s00508-023-02283-4
BibTeX
@article{Dawoud2024,
author = {Dawoud, Christopher and Widmann, Kerstin Melanie and Czipin, Sascha and Pramhas, Michael and Scharitzer, Martina and Stift, Anton and Harpain, Felix and Riss, Stefan},
title = {Efficacy of cx601 (darvadstrocel) for the treatment of perianal fistulizing Crohn’s disease—A prospective nationwide multicenter cohort study},
journal = {Wiener klinische Wochenschrift},
year = {2024},
doi = {10.1007/s00508-023-02283-4}
}
EUVIMED